RxDoctor Payments Data

Errol Singh, MD

Urology · Columbus, OHNPI 1629141577

Payments from drug & device makers

$8,123in general payments, 2019–2025

Across 56 payments — averaging $145.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$4K
  • EDAP Technomed Inc$4K
  • Astellas Pharma US Inc$178
  • Teleflex LLC$168
  • Medtronic$119
  • Myovant Sciences Inc.$101
  • plus $191 from 9 others

What the payments were for

  • Travel & lodging$6,34578%
  • Food & beverage$1,61320%
  • Education$1652%

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Procept Biorobotics Corporation17$3,826
EDAP Technomed Inc15$3,540
Astellas Pharma US Inc4$178
Teleflex LLC2$168
Medtronic1$119
Myovant Sciences Inc.5$101
Myriad Genetic Laboratories, Inc.1$50
Pfizer2$33
Ambu Inc.1$22
AbbVie1$21
AstraZeneca1$19
Neotract Inc.1$19
Endo Pharmaceuticals Inc.1$17
Agiliti Surgical, Inc.1$11
Innovative Medical Technologies, LLC3$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,123 in reported general payments places this provider in the 70th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$4,492
Medicare patients
20
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$14,461
Dutasteride23$1,206
Tamsulosin Hcl48$851
Testosterone Cypionate11$542
Finasteride63$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$178$14,46111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 485 urology providers in Ohio.

Other urology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →